文献速递肺栓塞与肺血管病

降钙素基因相关肽拮抗剂治疗偏头痛相关的肺动脉高压:病例系列

Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine: A Case Series.
PubMed 文献 · Chest · 2026-01-01

本文报告3例在接受降钙素基因相关肽(CGRP)靶向治疗期间经血流动力学确诊的肺动脉高压(PAH)患者,其中2例无传统PAH危险因素,1例疑似门静脉高压。所有患者肺血管阻力显著升高,2例在停用CGRP靶向治疗并启动PAH治疗后改善。作者认为时间关联与生物学合理性提示潜在安全信号,需进一步研究。

要点

  • 接受CGRP靶向治疗者出现心肺症状时应警惕PAH可能
  • 3例均肺血管阻力显著升高,2例停药并治疗PAH后改善
  • 因果关系尚不能确定,但提示需系统研究其心肺风险

核心结论

  • CGRP靶向治疗与PAH存在时间关联和生物学合理性,构成潜在安全信号,但尚不能推断因果关系。

研究设计与样本

  • 病例系列,报告3例在接受CGRP靶向治疗期间经血流动力学确诊PAH的患者。

主要发现

  • 2例缺乏传统PAH危险因素,第3例疑似门静脉高压。
  • 所有患者肺血管阻力显著升高。
  • 2例在停用CGRP靶向治疗并启动PAH治疗后改善。

关键数值与推荐

  • CGRP单克隆抗体2018年上市、gepants于2020年上市,现广泛用于偏头痛预防和急性治疗。
  • CGRP是强效内源性肺血管扩张剂,实验模型中其阻断可加重肺动脉高压。

临床怎么用

  • 对接受CGRP靶向治疗的偏头痛患者,应关注心肺症状并警惕PAH可能。

局限性

  • 病例数仅3例,无法推断因果关系。
  • 人类CGRP通路抑制的心肺风险尚未被系统研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calcitonin gene-related peptide (CGRP)-targeted therapies are a recent addition to the migraine field. Monoclonal antibodies became available in 2018 and gepants in 2020, both now widely used for migraine prevention and acute treatment. CGRP is also a potent endogenous pulmonary vasodilator, and its blockade worsens pulmonary hypertension in experimental models. Yet the cardiopulmonary risks of CGRP pathway inhibition in humans have not been studied systematically. We report 3 patients with hemodynamically confirmed pulmonary arterial hypertension (PAH) diagnosed while they were receiving CGRP-targeted therapy. Two patients lacked traditional PAH risk factors; the third patient had suspected portal hypertension. All patients presented with markedly elevated pulmonary vascular resistance, and 2 patients improved after CGRP-targeted therapy was discontinued and PAH treatment was initiated. Although causality cannot be inferred from these cases, the temporal association and biologic plausibility suggest a potential safety signal deserving of further study. Clinicians should remain vigilant for cardiopulmonary symptoms in patients receiving CGRP-targeted therapies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lu K, Barros LM, Murinova N, et al. Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine: A Case Series. Chest. 2026. PMID: 42264575. doi:10.1016/j.chest.2025.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。